B 4.4 Surgery for intermittent claudication  by unknown
Treatment of Intermittent Claudication 597
6·t Ballard [L, Sparks SR, Talor FC, Bergan 11, Smith DC, Bunt T], et
al. Complicatoins of iliac artery stent deployment. j Vase Surg
1996; 24: 545-555.
65. Becker Gj, Katzen BT, Dake MD. Noncoronary angioplasty.
Radiology 1989; 170: 921-940.
66. Matsi P], Manninen HI. Complications of lower-limb percuta-
neous transluminal angioplasty: a prospective analysis of 410
procedures on 295 consecutive patients. Cardiovasc Int Radiol
1998; 21: 361-366.
67. Gardiner GA [r, Meyerovitz MF, Stokes KR, Clouse ME,
Harrington DP, Bcttrnann MA. Complications of translurninal
angioplasty. Radiology 1986; 159: 201-208.
68. Kashdan Bj, Trost OW, jagust MB, Rackson ME, Sos TA, et al.
Retrograde approach for contralateral iliac and infrainguinal
percutaneous transluminal angioplasty: experience in 100
patients. jVIR 1992; 3: 515-521.
84.4
Surgery for Intermittent Claudication
B 4.4.1
Introduction
The most compelling indication for an open surgical
revascularisation procedure on the lower limb is
critical limb ischaemia (rest pain, tissue loss).
Therefore, surgical procedures are discussed in
greater breadth and depth in the section of the doc-
ument dealing with CLI (Section 04, Treatment of
Critical Limb Ischaemia, p 5163). The following sec-
tion addresses only the limited application of surgi-
cal procedures appropriate to the treatment of
patients with K'.
Surgery is rarely necessary in patients with IC; in
fact, surgery should be avoided initially and other
options pursued in most patients. The generalised
disease process present in patients with atheroscle-
rotic occlusive disease is not benefited by limb revas-
cularisation, other than the relatively minor consid-
erations that increasing exercise capacity may
improve conditioning and allow exercise therapy for
angina. The overriding consideration is that, in the
claudicant, the threat to life of generalised athero-
sclerosis takes priority over the limited threat to
limb of the peripheral lesions. In a non-limb-threat-
ening situation, conservative treatment will provide
sufficient improvement in most, so the risk of both
early and late complications associated with bypass
grafting cannot be justified. However, exceptional
circumstances do exist, and these deserve discus-
sion, for in practice, valid exceptions to the general
reservation against surgical revascularisation may
occur.
Ordinarily, if exercise therapy fails or is rejected
by the patient for other reasons, these patients may
try pharmacotherapy or be referred for imaging to
evaluate the possibility of balloon angioplasty. If
these options are not possible, or fail, surgery may
be considered. The decision to involves an individu-
alised risk:benefit analysis, balancing the benefit of
relieving that particular patient's disability against
the immediate risks (morbidity/mortality/technical
failure) and the risk of late failure of the proposed
surgical procedure. This weighing of risk and bene-
fit must be settled in the patient's favour.
B 4.4.2
Surgical Procedures
General considerations
Surgical procedures arc discussed separately in terms of
the results of their application to proximal or distal
disease, the common femoral artery being the bound-
ary. This is because not only is the patency durability
better for proximal disease but one often can treat both
legs with the same procedure. Even if a single-leg
bypass does not fail, claudication may return because
of progression of like lesions in the contralateral
extremity. The latter is not gauged by standard out-
come measures.
Continuing this comparison, distal procedures usu-
ally can be performed with a lower general and sys-
temic, but not local, morbidity rate than proximal pro-
cedures performed through abdominal incisions. The
use of prophylactic antibiotics has reduced the risk of
graft infections to a rare but disastrous occurrence,
whose risk is increased if there is a groin incision.'
Finally, although the overall cardiac mortality/mor-
bidity risk would seem intrinsically greater for those
proximal reconstructions involving aortic exposure
and clamping, this is balanced by the fact that those
with distal disease, specifically diabetic patients, gen-
erally have a higher prevalence of atherosclerotic
involvement of cardiac, renal, and other visceral circu-
lations. Their perioperative risk is as high and their
survival worse than proximal reconstructions.s>
Although these overall observations do not apply
specifically to patients with IC, a peripheral/distal
procedure cannot be assumed to be inherently less
risky than a proximal one and thus easier to justify in
a claudicant.
The patency rate for operations to treat inflow dis-
ease (aortoiliac occlusive disease) is also better than
that of fernoropopliteal bypass. There are few direct
comparative data in equivalent cases indicating which
type of bypass graft (extraanatomic ys anatomic, uni-
Eur j Vase Endovasc Surg Vol 19 Supplement A, june 2000
S98 Treatment of Intermittent Claudication
lateral vs bilateral, and bypass assisted by PTA) is the
most appropriate in the patient suffering from IC4,5
The choice is generally based on arteriographic find-
ings and patient risk, but most patients with IC who
would be accepted for bypass would be good risk
with single-level disease. Given that, current feeling is
to perform the lesser operative procedure capable of
producing high and durable patency.
Proximal disease
With disease confined to the aortoiliac segments, the
preferred operation is an aortofemoral (usually bilat-
eral) bypass or an extended endarterectomyP The
results of these procedures are reasonably good, with
an operative mortality rate of 1% to 4% and a 5-year
patency of 85% to 90%, with the results for patients
with IC being on the better side of these ranges.w
Modern perioperative care has further improved the
results and safety of the reference operation aorto-
bifernoral bypass, which allows treatment of both legs
with a single operation and provides the best durabil-
ity. In a meta-analysis, De Vries and Hunink'' reviewed
8,123 operations with an operative mortality of 3.3%,
and the patency rates for that subset of patients with
claudication were as shown (Table 27). This mortality
rate applies to reported series dating back to 1975. It
can be presumed that the current mortality rate for
claudicants undergoing proximal bypass is closer to
1% than 2%.
Sexual dysfunction has been a concern in the opera-
tive treatment of proximal disease in sexually active
men, but by avoidance of the hypogastric plexus and
selection of bypass based on careful preoperative
study of the arteriogram," this type of complication
can be minimised and sexual function improved after
proximal bypass. Improved results with respect to
erectile dysfunction have also been reported after
endarterectomy.t-P
Axillobifemoral bypass is an extra-anatomic bypass
that reduces the risk of proximal reconstruction by
avoiding an abdominal incision with aortic dissection
and clamping. However, its primary patency is inferi-
or to aortobifernoral bypass and, in spite of improving
results, it is still not recommended for the treatment of
Table 27: Patency at 5 and 10 years after aortobifemoral bypass
IC In the case of unilateral iliac artery occlusion or
extensive disease within one iliac artery not amenable
to PTA and stenting, there is a role for limited proce-
dures such as iliofemoral or crossover femorofemoral
bypass grafts, the latter even in combination with
donor iliac artery dilatation, because they lessen oper-
ative morbidity while yielding acceptable results.14.15.16
In fact, in the absence of distal, that is, superficial
femoral artery occlusion, which is the case with most
patients with IC, femorofemoral bypass carries a sim-
ilar patency to aortobifemoral bypass.v
In summary, proximal bypasses in patients with IC
offer primary patency rates in the 80% to 90% range,
and, if the appropriate patient and bypass are
matched, reasonable morbidity and mortality rates
(close to 1%). Their greater durability and degree of
symptom relief may be a reasonable trade-off for the
immediate morbidity in active good-risk patients with
IC whose aortoiliac lesions are not suitable for PTA
and stent.
Distaldisease
Extensive infrainguinal occlusive disease requIrIng
bypass to infrapopliteal arteries, or to a popliteal
artery with significant runoff disease but causing only
claudication, very rarely justifies surgical interven-
tion. In rare patients with extensive disease and severe
claudication, there have been reports of successful tib-
ial bypass.w'? If the disease is confined to the superfi-
cial femoral artery and the distal vessels are relatively
disease free, bypass may be justified in selected
patients, following previously stated principles and
strategies.
Controversy remains about the use of autogenous
vein versus prosthesis in above-knee bypass. The argu-
ments are summarised in Table 28. Those favouring
above-knee prosthetic bypass point out that (1) paten-
cy is close enough to autogenous vein that most series
fail to show statistically significant difference and (2) it
preserves vein for other, later uses. The opposing point
of view insists that autogenous vein is better and
should be used first and that other or later need for the
vein is only 5% to 10%.20 Because below-knee patency
is better than above-knee patency for autogenous
Patency (range in sensitivity)
Sy 10 Y
Limb-based claudication
Patient-based claudication
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85.8 (85-89)
86.8 (85-92)
79.4 (78-83)
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Table 28: Benefits of vein versus prosthetic grafts for above-knee femoropopliteal bypass
S99
In favour of vein In favour of prosthesis
• Better long-term patency rates • Close to equivalent long-term patency rates
• Avoidance of "staged" approach to femoral popliteal • Better combined patency rates with prosthesis first, vein second
reconstruction (ie, best operation first time) if the need for secondary reconstructions is considered
• Other graft material (ie, internal mammary arteries) are • Fewer wound complications
available for those patients requiring coronary artery bypass.• Vein available for secondary or coronary bypass
• Need for other use overestimated. • Shorter operative time
• Lower risk of graft infection
Table 29: Patency data for bypass grafts in patients with intermittent claudlcatlon>
5-year primary patency
Baseline Sensitivity analysis
Vein bypass
PTFE (above knee)
PTFE (below knee)
80 (2)
75 (3)
65 (6)
78-87
67-83
56-76
Critical Issue 16: Conduit for femoropopliteal
bypass
There is a need for further studies to resolve the
debate regarding the most appropriate conduit for
an above-knee femoral popliteal bypass.
femoropopliteal bypass,» this would favour bypass to
the below-knee popliteal segment.'? However,
although the available data do not allow absolute rec-
ommendations, most surgeons either would withhold
surgery for such claudicators or use above-knee pros-
thetic bypass.
The evaluation of results for different grafts in
patients with IC is complicated by the fact that most
authors report success rates for a given operation with
no substratification for indications for operation. The
combinations of procedures and variability of graft
material inhibit the interpretation of patency data. For
reconstruction of the aortoiliac segment, prosthetic
material (Dacron or expanded polytetrafluorethylene
[ePTFE])with or without external support is used with-
out clear preference. For infra inguinal reconstruction,
possible graft materials include ePTFE, glutaraldehyde-
treated human umbilical vein [HOY], Dacron, and
autologous vein (Table 28).22.23·2~ Further discussion of
these details is undertaken in D 4, Treatment of Critical
Limb Ischaemia (p 5163), but some comparative data
are available for claudicants. The best patency data
available come from the meta-analysis by Hunink et
alp the data for IC being as shown (Table 29).
B 4.4.3
Summary: Surgery for Intermittent Claudication
To benefit from surgery, it is not only important that
the patencies be high, but rather that mortality and
morbidity rates be kept low. Although it is generally
accepted that surgical mortality should be less than
5% when dealing with both patients with IC and those
with severe ischaemia, this should be significantly
lower before considering surgery for claudication.
One must take into account that the expected 5-year
survival rate for claudicants treated without surgery is
as high as 87%, an estimated risk of limb loss of only
1% per year, and a required intervention rate of 6% per
year for limb salvageP From the Swedish Vascular
Registry, it has recently been calculated that during
the lO-year period 1987 to 1996, the combined mortal-
ity and amputation rate was 2.2% for aortofemoral
reconstruction, 1.4% for femoropopliteal reconstruc-
tion, and 2.0% for distal reconstructions, so results are
improving.e' This and patency rates that are pre-
dictably 20% or more above those of PTA and stents
for a given lesion will preserve a role for surgical
bypass in claudicants, albeit a very selective one.
Recommendation 37: Surgery for intermittent
claudication
• Surgery should be offered to treat severe symp-
toms Dilly after other forms of medical therapy
have been recommended and have either failed or
been rejected for good reason.
• If used, surgery for IC should employ the proce-
dure offering extended clinical benefit, ie, one
with a high benefit-to-risk ratio.
• If necessary, surgery is the treatment of choice of
type 0 lesions but may be used also in type Band
C lesions (see Recommendation 32, p 583, and
Critical Issue 10, p 583).
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Lumbar sympathectomy
No objective evidence supports the use of lumbar
sympathectomy in the treatment of IC.25 Neither rest-
ing nor exercise blood flow is increased by the per-
formance of a syrnpathectomy.e
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B 4.5
Comparison of Therapeutic Options for
Intermittent Claudication
There is overwhelming evidence that walking capaci-
ty is increased by exercise. The timing and type of
exercise has been extensively studied, and supervised
frequent exercise sessions offer significant benefit in
increasing claudication distance (see B 4.1.2, Basic
Treatment, p 568).1 The question as to whether exercise
is superior to limited interventions such as balloon
angioplasty (PTA) is more controversial. In a study
from the United Kingdom, in which patients were fol-
lowed-up for 6 years, ABPI increased during the first
15 months after PTA; however, more significant
changes in walking distances were seen in the exercise
group. At 6 years' follow-up, there were no differences
between groups- (see also Recommendation 29, p
573). The loss of the initial advantage of PTA was
attributable to restenosis of the dilated segment,
whereas those treated conservatively had a steadily
increasing benefit of exercise. The later loss of advan-
tage of exercise was probably due to lack of adherence
to the exercise program. The best effect of exercise was
found in patients with disease confined to the superfi-
cial femoral artery, in contrast to PTA, which has the
best effect in iliac lesions.
In a second British study screening 600 patients
with Ie during follow-up of 6 months, PTA patients
benefited more in walking distance and ABPI than
those randomised to exercise.' The report on quality of
life recorded a better response after PTA than after
exercise. However, when the same group reported
